Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy
- 23 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical and Translational Oncology
- Vol. 23 (6), 1185-1192
- https://doi.org/10.1007/s12094-020-02509-1
Abstract
Background The prognostic value of neutrophil-to-lymphocyte ratio (NLR) has been extensively studied in cancer patients. However, the performance of NLR as an early marker of efficacy of immune checkpoint inhibitors (ICI) is still understudied. We studied the utility of NLR at baseline (bNLR), before the second dose of immunotherapy (NLR2) and the NLR trend for predicting efficacy outcomes. Methods We included all patients with advanced cancer treated with ICI from June 2013 to April 2019 at La Paz University Hospital, Madrid (Spain). We examined bNLR, NLR2 and NLR trend and explored the association with progression-free survival (PFS) at 6 months, median PFS and overall survival (OS). Results We included 211 patients. PFS and OS were significantly longer in the low bNLR group than in the high bNLR group [HR 0.71 (95% CI 0.60–0.84) and HR: 0.66 (95% CI 0.55–0.79), respectively]. Regarding NLR2, patients with low NLR2 had significantly longer PFS and OS than patients with high NLR2 [HR 0.67 (95% CI 0.57–0.79) and HR: 0.60 (95% CI 0.50–0.72), respectively]. Finally, for NLR trend, PFS and OS for patients with NLR trend < 1 were significantly longer than those patients with NLR trend ≥ 1 [HR 0.59 (95% CI 0.43–0.82) and HR 0.63 (95% CI 0.44–0.90), respectively]. At the multivariate analysis for PFS and OS, bNLR, NLR2 and NLR trend were all independent prognostic factors for PFS and OS. Conclusions bNLR, NLR2 and NLR trends are independent prognostic factors for survival in patients on immunotherapy. The dynamics of NLR in patients on immunotherapy is a promising marker that needs further investigation.Keywords
This publication has 30 references indexed in Scilit:
- Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibodyCancer Immunology, Immunotherapy, 2018
- Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma populationBritish Journal of Dermatology, 2018
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinomaJournal for ImmunoTherapy of Cancer, 2018
- Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitorsEuropean Journal of Cancer, 2018
- Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With NivolumabClinical Lung Cancer, 2017
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta -analysisCritical Reviews in Oncology/Hematology, 2017
- Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab TreatmentEBioMedicine, 2017
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancerLung Cancer, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016